Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Geelong, Victoria, Australia.
Barwon Health, University Hospital Geelong, Geelong, Victoria, Australia.
Acta Psychiatr Scand. 2024 Apr;149(4):332-339. doi: 10.1111/acps.13660. Epub 2024 Jan 19.
Several psychiatric disorders and medications used to treat them appear to be independently associated with skeletal deficits. As there is increasing evidence that lithium possesses skeletal protective properties, we aimed to investigate the association between lithium use and bone health in a group of women with bipolar disorder.
Women with bipolar disorder (n = 117, 20+ years) were recruited from south-eastern Australia. Bipolar disorder was confirmed using a clinical interview (SCID-I/NP). Bone mineral density (BMD; g/cm ) was measured at the spine, hip and total body using dual-energy x-ray absorptiometry and low bone mass determined by BMD T-score of <-1.0. Weight and height were measured, socioeconomic status (SES) determined and information on medication use and lifestyle factors self-reported. Linear and logistic regression were used to test associations between lithium and (i) BMD and (ii) low bone mass, respectively.
Thirty-five (29.9%) women reported current lithium use. Lithium users and non-users differed in regard to SES and BMD; otherwise, groups were similar. After adjustments, mean BMD among lithium users was 5.1% greater at the spine (1.275 [95% CI 1.229-1.321] vs. 1.214 [1.183-1.244] g/cm , p = 0.03), 4.2% greater at the total hip (0.979 [0.942-1.016] vs. 0.938 [0.910-0.966] g/cm , p = 0.03) and 2.2% greater at the total body (1.176 [1.148-1.205] vs. 1.150 [1.129-1.171] g/cm , p = 0.08) compared to participants not receiving lithium. Lithium users were also less likely to have low bone mass (22.9% vs. 43.9%, p = 0.031). Associations persisted after adjustment for confounders.
These data suggest lithium is associated with greater BMD and reduced risk of low bone mass in women with bipolar disorder. Research into the underlying mechanisms is warranted.
几种精神疾病和用于治疗这些疾病的药物似乎与骨骼缺陷独立相关。由于越来越多的证据表明锂具有骨骼保护特性,我们旨在调查一组患有双相情感障碍的女性中锂使用与骨骼健康之间的关联。
从澳大利亚东南部招募了患有双相情感障碍的女性(n=117,年龄 20+岁)。使用临床访谈(SCID-I/NP)确认双相情感障碍。使用双能 X 射线吸收法测量脊柱、臀部和全身的骨矿物质密度(BMD;g/cm),并通过 BMD T 评分<-1.0 确定低骨量。测量体重和身高,确定社会经济地位(SES),并报告药物使用和生活方式因素的信息。使用线性和逻辑回归分别测试锂与(i)BMD 和(ii)低骨量之间的关联。
35 名(29.9%)女性报告目前正在使用锂。锂使用者和非使用者在 SES 和 BMD 方面存在差异;否则,两组相似。调整后,锂使用者的脊柱 BMD 平均增加 5.1%(1.275 [95%CI 1.229-1.321] vs. 1.214 [1.183-1.244] g/cm,p=0.03),全髋 BMD 平均增加 4.2%(0.979 [0.942-1.016] vs. 0.938 [0.910-0.966] g/cm,p=0.03),全身 BMD 平均增加 2.2%(1.176 [1.148-1.205] vs. 1.150 [1.129-1.171] g/cm,p=0.08)与未服用锂的参与者相比。锂使用者发生低骨量的可能性也较低(22.9% vs. 43.9%,p=0.031)。调整混杂因素后,关联仍然存在。
这些数据表明,锂与双相情感障碍女性的 BMD 增加和低骨量风险降低有关。有必要研究潜在的机制。